Brush up on your midgut anatomy because the quality of life data from the 2017 NETTER-1 trial shows Lu-177 Dotatate, as compared to octreotide, enables patients with GI neuroendocrine tumors not only to live (much!) longer without disease but also to live better. | Strosberg, J Clin Oncol 2018


Popular Posts